world congress of cardiology 2014 melbourne , page-4

Good point. While conferences are great, it's true that clinicians can offer some resistance to taking up new technologies but the actual target market i.e. patients/the general public ultimately has some say in what treatment they receive e.g. you can opt for different brands of medication if the prescribed formulation and dosage is the same. So if everyone were aware of the superiority of Cardiocel to current treatment options, increased patient demand can put a bit of pressure on surgeons to get on board with Cardiocel faster. More media coverage is key.

Also agree with meerkat. It makes little sense why there hasn't been a rise in sp already given 2 positive announcements (c.f. the change with RHT with news of FDA approval for software, which is much easier to obtain than approval for an implantable product like Cardiocel). But as frustrating as it is, speculating why doesn't change the sp, or make it rise faster. Medical research isn't like digging something out of the ground and selling it - it takes time. And a lot of it. Have a bit of faith in the company and top up if you're able. :)